bs-5193R-BF350 [Conjugated Primary Antibody]
AKT1+2+3 (Tyr315+316+312) Antibody, AbBy Fluor® 350 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: AKT1+2+3 Tyr315+316+312

Specificity: This antibody will detect AKT 1 when phosphorylated at Tyr315 in Human, Mouse, Rat or Bovine; AKT2 when phosphorylated at Tyr316 in Human, Mouse, Rat, or Bovine; and AKT3 when phosphorylated at Tyr312 in Human, Mouse, Rat, or Bovine.

Modification Site: Tyr315+316+312

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 207, 208, 10000

Source: KLH conjugated synthetic phosphopeptide derived from human AKT1 around the phosphorylation site of Tyr315

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

AKT, also known as protein kinase B (PKB), is a 57 kDa serine/threonine protein kinase. There are three mammalian isoforms of Akt: AKT1 (PKB alpha), AKT2 (PKB beta) and AKT3 (PKB gamma) with AKT2 and AKT3 being approximately 82% identical with the AKT1 isoform. Each isoform has a pleckstrin homology (PH)domain, a kinase domain and a carboxy terminal regulatory domain. AKT was originally cloned from the retrovirus AKT8, and is a key regulator of many signal transduction pathways. Its tight control over cell proliferation and cell viability are manifold; overexpression or inappropriate activation of AKT has been seen in many types of cancer. AKT mediates many of the downstream events of phosphatidylinositol 3 kinase (a lipid kinase activated by growth factors, cytokines and insulin). PI3 kinase recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus.

Conjugation: AbBy Fluor® 350

Excitation/ Emission: 346nm/442nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
FCM(1:20-100)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 56


Cross Reactive Species: Human
Mouse
Rat

Predicted Cross Reactive Species: Dog
Cow
Sheep
Pig
Chicken
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Iriyama et al. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. (2016) Cancer.Med. 5:3223-3234Read more>>
  • Wang X et al. MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. Cancer Cell Int. 2020 Feb 28;20:63.Read more>>
  • Zhu X et al. Knockdown of ALPK2 inhibits the development and progression of Ovarian Cancer. Cancer Cell Int. 2020 Jun 24;20:267.Read more>>
  • Chen R et al. Tongmai Yangxin pill reduces myocardial no-reflow by regulating apoptosis and activating PI3K/Akt/eNOS pathway. J Ethnopharmacol. 2020 Oct 28;261:113069.Read more>>
  • Wenjun Zheng. et al. EIF3H Knockdown Inhibits Malignant Melanoma through Regulating Cell Proliferation, Apoptosis and Cell Cycle. Exp Cell Res. 2021 Jan;:112488Read more>>
  • Yongjun Zhu. et al. POLE2 knockdown reduce tumorigenesis in esophageal squamous cells. Cancer Cell Int. 2020 Dec;20(1):1-12Read more>>
  • Jinxing Yang. et al. Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells. Int J Oncol. 2021 May;58(5):1-12Read more>>
  • Qingke Chen. et al. Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration. Cancer Cell Int. 2021 Dec;21(1):1-12Read more>>
  • Chen Wenchao. et al. CDC42EP3 is a key promoter involved in the development and progression of gastric cancer. Carcinogenesis. 2021 JuRead more>>
  • Mingliang Zhang. et al. HSPA4 Knockdown Retarded Progression and Development of Colorectal Cancer. Cancer Manag Res. 2021; 13: 4679C469Read more>>
  • Jingjing Liu. et al. CHSY1 is upregulated and acts as tumor promotor in gastric cancer through regulating cell proliferation, apoptosis, and migration. 2021 Aug 19Read more>>
  • Jingcheng Hao. et al. Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma. Oncol Rep. 2021 Nov;46(5):1-11Read more>>
  • Peng Xu. et al. Deduction of CDC42EP3 suppress development and progression of osteosarcoma. Exp Cell Res. 2022 Jan;:113018Read more>>
  • Xusheng Du. et al. RIOK3-mediated Akt phosphorylation facilitates synergistic replication of Mareks disease and reticuloendotheliosis viruses. VIRULENCE. 2022 Jul 06Read more>>
  • Xing Chang. et al. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. TOXICOL APPL PHARM. 2022 Sep;450:116156Read more>>
  • Huaqing Chen. et al. Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3K-AktCmTOR pathway. PHARMACOL RES PERSPE. 2022 Dec;11(1):e1041Read more>>
  • Abulaiti Abulizi. et al. Quince extract resists atherosclerosis in rats by down-regulating the EGFR/PI3K/Akt/GSK-3 pathway. BIOMED PHARMACOTHER. 2023 Apr;160:11433Read more>>
VALIDATION IMAGES